Open an account

Genelux

GNLX · NASDAQ

$2.50+$0.05 (+2.04%)TodayMarket closed ·
Prev close $2.45

About GNLX

Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 25 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

Employees
25
Headquarters
Westlake Village, California
Listed
Jan 26, 2023
Sector
Health Care
Industry
Biotechnology
Website
genelux.com

GNLX key statistics

Market cap
113.11M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
243.90K
Volume
331.73K
Open price
$2.43
High today
$2.61
Low today
$2.43
52 Week high
$8.54
52 Week low
$2.29

Genelux (GNLX) at a glance

Genelux (GNLX) last traded at $2.50, with a market cap of 113.11M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.43 and $2.61. The current price is 2.9% above the day's low and 4.3% below its high.

Volume so far is 331.73K shares, above the average of 243.90K shares a day.

Over the past year Genelux has ranged from $2.29 to $8.54, and now sits 3% of the way up that range.

Genelux met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.21 per share against an estimate of -$0.2006.

The average analyst price target is $19.38, 675.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $19.38
Low
$12.12
Now
$2.50
High
$32.55

GNLX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 6.7% on average.

  1. Q3 FY24: reported -$0.19 per share against an estimate of -$0.1904
  2. Q4 FY24: reported -$0.26 per share against an estimate of -$0.1862
  3. Q1 FY25: reported -$0.21 per share against an estimate of -$0.2474
  4. Q2 FY25: reported -$0.20 per share against an estimate of -$0.2193
  5. Q3 FY25: reported -$0.21 per share against an estimate of -$0.2162
  6. Q4 FY25: reported -$0.25 per share against an estimate of -$0.2227
  7. Q1 FY26: reported -$0.20 per share against an estimate of -$0.1836
  8. Q2 FY26: reported -$0.21 per share against an estimate of -$0.2006

GNLX news

  • Press releaseGlobe Newswire

    Genelux Corporation to Participate in Upcoming Conferences

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseBusiness Wire

    Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors

  • Avi Kapoor

    Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

  • Avi Kapoor

    Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Genelux

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.